Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
David Stegner: How Fundamental Platelet Research Can Translate Into Therapeutic Innovation
Apr 7, 2026, 15:59

David Stegner: How Fundamental Platelet Research Can Translate Into Therapeutic Innovation

David Stegner, Professor of Vascular Imaging at the Julius Maximilians University of Würzburg, reposted from Boehringer Ingelheim on LinkedIn:

”A strong example of how fundamental platelet research can translate into therapeutic innovation.

Work from University Hospital of Würzburg has identified GPVI as a key driver of thrombo-inflammation in acute ischemic stroke, directly linking platelet biology to clinical outcome.

The collaboration between Boehringer Ingelheim and Emfret Analytics now advances this concept toward clinical application.

Targeting GPVI offers a compelling strategy: inhibiting pathological platelet activation while preserving hemostasis – a critical requirement in stroke therapy.

For the field, this marks an important translational milestone.

For patients, it highlights the potential to improve outcomes beyond current standard-of-care.”

Quoting Boehringer Ingelheim‘s post:

”NEWS: We are collaborating with Emfret Analytics to advance a potential first‑in‑class antibody‑based approach for acute ischemic stroke.

For decades, we have helped transform stroke care.

By targeting the platelet receptor GPVI, this new approach aims to inhibit thrombus formation and growth while maintaining normal hemostasis – designed to complement standard‑of‑care therapies and further improve patient outcomes.”

David Stegner: How Fundamental Platelet Research Can Translate Into Therapeutic Innovation

Stay updated with Hemostasis Today.